Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 293 results for breast cancer

  1. Microwave ablation for primary or metastatic cancer in the lung (IPG716)

    Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).

  2. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued [GID-TA10539]

  3. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued [GID-TA11178]

  4. Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]

    Discontinued [GID-TAG410]

  5. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781

    Awaiting development [GID-TA11110] Expected publication date: TBC

  6. AlignRT for intracranial stereotactic radiosurgery (MIB147)

    NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .

  7. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Awaiting development [GID-TA11339] Expected publication date: TBC

  8. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development [GID-TA11022] Expected publication date: TBC

  9. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued [GID-TAG391]

  10. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued [GID-TAG432]

  11. Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]

    Discontinued [GID-TA10327]

  12. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued [GID-TA10028]

  13. Prostate cancer: diagnosis and management (NG131)

    This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.

  14. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued [GID-TAG390]